Скачать или смотреть Entering A New Era of C3G Care with Pegcetacoplan, with Carla Nester, MD

Pegcetacoplan’s FDA approval marks a major milestone in the treatment of C3 glomerulopathy (C3G) and immune complex membranoproliferative glomerulonephritis (IC-MPGN), particularly in populations with high unmet need, including transplant recipients and pediatric patients.

In this interview with HCPLive, Carla Nester, MD, the Jean E. Robillard Chair in Pediatric Nephrology and the director of the Pediatric Glomerular Disease Clinic at the University of Iowa, emphasizes how transformational it is to now have 2 approved complement inhibitors—pegcetacoplan, a C3 inhibitor, and iptacopan, a factor B inhibitor—targeting the core enzymes of the alternative pathway.

Learn more: https://www.hcplive.com/view/entering...

#Nephrology #Kidney #KidneyDisease #RareDisease #Doctor #Medicine